Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05123391 |
| Other study ID # |
210406002 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
June 22, 2021 |
| Est. completion date |
June 22, 2024 |
Study information
| Verified date |
April 2024 |
| Source |
Pontificia Universidad Catolica de Chile |
| Contact |
Tomas Merino, MD |
| Phone |
56-223543346 |
| Email |
tmerino[@]med.puc.cl |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This is a prospective, interventional pilot study to evaluate the feasibility of randomizing
patients diagnosed with prostate cancer to different treatment schemes according to their
risk.
Patients with a diagnosis of prostate adenocarcinoma (confirmed by biopsy), without signs of
metastasis outside the pelvis in the staging study and without prior radiotherapy (RT) to the
pelvic region will be recruited.
The definition of risk group from the international guide National Comprehensive Cancer
Network will be used.
- Low risk
- Favorable intermediate risk
- Unfavorable intermediate risk
- High risk The use of hormonal blocking will be at the discretion of each treating
physician.
The radiotherapy simulation will be carried out according to the institutional protocol for
the treatment of prostate cancer.
According to the risk group of the patients, the following randomization will be carried out:
- Low / intermediate favorable risk: Patients will be randomized to receive SBRT to
prostate 36.25 Gy in 5 fractions, alternate days or weekly, with VMAT (technique and 6
Mega-voltage (MV) X-rays vs to SBRT to prostate 26 Gy in 2 fractions, 1 weekly fraction,
with VMAT technique and 6 Mv X-rays. The volumes to be treated, ¨Clinical target volume¨
(CTV) will be defined as the prostate, according to the consensus of the Radiation
Therapy Oncology Group (RTOG).
- Intermediate unfavorable risk and high risk: Patients will be randomized to receive SBRT
to the prostate and seminal vesicles, 36.25 Gy in 5 fractions, alternate days or weekly,
with VMAT technique and 6 MV X-rays vs SBRT to pelvis scheme of 25 Gy in 5 fractions
with simultaneous integrated boost up to 36.25 to the prostate and seminal vesicles,
with the same technique.
- Patients with positive pelvic node: Will be randomized to moderate hypofractionated RT ,
completing a dose of 44 Gy in 20 fractions to the pelvis with a simultaneous integrated
boost up to 54-60 Gy in 20 fractions to metastatic lymphadenopathy and prostate with
seminal vesicles, completing 60 Gy to prostate and seminal vesicles or to ultra
hypofractionated RT to the prostate and macroscopic lymphadenopathy to 35 and 30-35 Gy
respectively and 25 Gy in 5 fractions to the elective nodal areas.
Description:
Background
Prostate cancer is the most common non-cutaneous neoplasm in men both worldwide and in Chile,
being the third cause of death in our country. Radiation therapy (RT) is a well-validated
curative treatment alternative for prostate cancer, generally being combined with androgen
deprivation therapy in intermediate and high risk patients. Dose escalation of RT improves
event-free survival and the need for new therapies in the future (continuous androgen
deprivation). This dose escalation strategy involves long-term treatments (7 to 8 weeks) with
high operational cost for the patient (stays, transportation, etc.) and radiotherapy
services.
Hypofractionated RT (reduction of treatment fractions) has shown a similar safety profile and
oncological results equivalent to dose escalation in several phase III studies, allowing the
total treatment time to be reduced to 4-5 weeks and thus be a more convenient treatment for
patients and the radiotherapy department. In the same way, radiosurgery or stereotaxic body
radiotherapy (SBRT), is a highly conformed RT technique that significantly reduces the total
treatment time (1-2 weeks of treatment). In recent years, the safety and efficacy of SBRT in
low- and intermediate-risk prostate cancer has been proven in phase III studies; and in
high-risk patients, its low toxicity profile and good biochemical control have been
demonstrated in a systematic review. Since this radiotherapy technique has recently been
introduced into clinical practice, there are different approaches in relation to the number
of fractions used and volumes to be treated.
A pilot study was designed to evaluate the technical feasibility of implementing the
randomization of patients who are candidates for radiosurgery between schemes previously used
in the literature according to their risk and stage: 2 vs 5 fractions in low / intermediate
risk patients include or not pelvic treatment in high-risk patients and a moderate
hypofractionated treatment regimen of 20 vs 5 fractions in cN1 or higher patients.
Methods
This is a prospective, interventional pilot study to evaluate the feasibility of randomizing
patients diagnosed with prostate cancer to different treatment schemes according to their
risk.
Patients with a diagnosis of prostate adenocarcinoma (confirmed by biopsy), without signs of
metastasis outside the pelvis in the staging study and without prior RT to the pelvic region
will be recruited.
The definition of risk group from the international guide National Comprehensive Cancer
Network will be used.
- Low risk
- Favorable intermediate risk
- Unfavorable intermediate risk
- High risk
The use of hormonal blocking will be at the discretion of each treating physician.
The radiotherapy simulation will be carried out according to the institutional protocol for
the treatment of prostate cancer.
According to the risk group of the patients, the following randomization will be carried out:
- Low / intermediate favorable risk: Patients will be randomized to receive SBRT to
prostate 36.25 Gy in 5 fractions, alternate days or weekly, with Volumetric modulated
arc therapy technique (VMAT) and 6 Mv X-rays vs to SBRT to prostate 26 Gy in 2
fractions, 1 weekly fraction, with VMAT technique and 6 Mv X-rays. The volumes to be
treated, ¨clinical target volume¨ (CTV) will be defined as the prostate, according to
the consensus of the RTOG.
- Intermediate unfavorable risk and high risk: Patients will be randomized to receive SBRT
to the prostate and seminal vesicles, 36.25 Gy in 5 fractions, alternate days or weekly,
with VMAT technique and 6 Megavolts MV X-rays vs SBRT to pelvis scheme of 25 Gy in 5
fractions with simultaneous integrated boost up to 36.25 to the prostate and seminal
vesicles, with the same technique.
- Patients with positive regional pelvic nodes: Patients will be randomized to moderate
hypofractionated RT, completing a dose of 44 Gy in 20 fractions to the pelvis with a
simultaneous integrated boost up to 54-60 Gy in 20 fractions to metastatic
lymphadenopathy and prostate with seminal vesicles, completing 60 Gy to prostate and
seminal vesicles or to ultra-hypofractionated RT to the prostate and macroscopic
lymphadenopathy to 35 and 30-35 Gy respectively and 25 Gy in 5 fractions to the elective
nodal areas.
Contouring of the prostate, seminal vesicles and pelvis will be performed according to the
consensus of the NRG Oncology Group.
The treatment will be delivered at the Radiotherapy Service of the Cancer Center, in the a
linear accelerator unit with daily verification images.
Before starting treatment and during follow ups urinary symptoms will be assessed by the
International Prostate Symptom Score (IPSS) scale, and the The National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE) and quality of life with "The Expanded
Prostate Cancer Index Composite "v2.0 (EPIC 2.0), and the European Organisation for Research
and Treatment of Cancer (EORTC) quality of life questionnaire-30 (QLQ-30 and QLQ-PR25). The
patient will be monitored weekly during the delivery of radiation therapy to assess acute
toxicity.
The last day of radiotherapy will be counted as day zero, and the patient will be monitored
after 30 days, then every 6 months with IPSS, CTCAE, EPIC, QLQ-30, QLQ-PR25 and prostate
specific antigen (PSA) according to the follow-up protocol.
A randomization feasibility trial was designed for each of the 3 groups of patients, assigned
1: 1 for different interventions in each group. The CONSORT recommendations and the Lewis et
al method were followed to calculate the sample size and define the feasibility objectives,
respectively.
Three key objectives were defined to assess the feasibility of the trial: recruitment
acceptance (Percentages of selected patients recruited), treatment fidelity, and patient
retention (follow-up). An exact 1-tailed binomial test was used with 5% significance and 80%
power.
The feasibility criteria will correspond to:
1. Recruitment: At least 80% (green indicator) of eligible patients must be recruited, the
trial will not be feasible if recruitment uptake is less than or equal to 40% (red
indicator).
2. Treatment fidelity: A high level of treatment fidelity is required with 80% or more
(green indicator) of patients receiving the treatment plan without major protocol
deviations, if less than 40% of patients comply with this indicator (red indicator) the
test will not be feasible.
3. Follow-up: At least 80% (green indicator) of the patients must remain in follow-up to
meet feasibility, if 40% or less (red indicator) comply with retention, the trial will
not be feasible.
For this feasibility study a sample size of 30 patients is calculated (5 for each branch of
the protocol).
This sample size calculation and feasibility criteria will be used for each of the 3 groups
of patients.
In the case an indicator in the red zone the study will stop, in the case all the indicators
are in green, a follow up study will be carried out, in the case any indicator is yellow
(between 80% and 40%), the pertinent corrections will be made to proceed to a further study.
